
Opinion|Videos|May 14, 2024
Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
Evaluating Pharmacists’ Role In Veterinary Medication Management and Education
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5



























